- BeyondSpring Inc BYSI presented data from the lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia (DIN) in non-small cell lung cancer (NSCLC) patients.
- In summary, data from 101 and 103 studies, plinabulin demonstrated a superior benefit for Gr4N, Gr3/4N, all GrN, and duration of severe neutropenia (DSN) compared to the control. There was a reduction in mean DSN of >1 day for plinabulin vs. control.
- In the 105 study, NSCLC pts with at least one febrile neutropenia (FN), plinabulin was superior for preventing DIN and hematologic complications vs. control: Grade 4 Neutropenia: 17% with plinabulin vs. 40% with placebo.
- Related: BeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 Hours.
- In addition, the mean DSN was 0.43 days for plinabulin vs. 1.32 days for placebo.
- There was also a good quality of life and safety profile with plinabulin.
- In summary, despite a higher frequency of ANC sampling in cycle 1, plinabulin was superior vs. no-treatment for DIN and hematologic complications.
- Quality of life was maintained, and there were minimal adverse effects, including minimal bone pain burden in the plinabulin arm vs. no treatment.
- Price Action: BYSI shares are up 30.7% at $0.99 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
